as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹14.32
Change
-1.08 (-7.01%)
Open
₹15.94
Prev. Close
₹15.4
Day High
₹15.94
Day Low
₹14.0
Volume Analysis
Traded
24,835
Delivered
19,904
Delivery %
80.14%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong operating margin (35.62%)
Weaknesses (3)
- •Low return on equity (-2.24%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (31/100)
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹17.44 | ₹16.69 | ₹15.5 | ₹14.75 | ₹13.56 | ₹12.81 | ₹11.62 |
| Fibonacci | ₹16.69 | ₹15.95 | ₹15.49 | ₹14.75 | ₹14.01 | ₹13.55 | ₹12.81 |
| Camarilla | ₹14.85 | ₹14.68 | ₹14.5 | ₹14.75 | ₹14.14 | ₹13.96 | ₹13.79 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
-12.79%
1 Month
+2.95%
3 Months
-23.55%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-2.5%
Net margin -4.43% × asset turnover 0.27x × equity multiplier 2.09x
Company Overview
Sector
Healthcare
Market Cap
₹35 Cr
ROE
-2.24%
Book Value
₹42.6
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.
TopFund Analysis
Vivo Bio Tech Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 31/100. The strongest factor is Financial Strength (66/100), while Growth (3/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (35.62%); low return on equity (-2.24%); promoter holding is falling.
TopFund Score — Fundamentals Quality
31/100 — WeakData confidence: 71/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Stock is trading at 0.37 times its book value
- −Company has low interest coverage ratio.
- −Promoter holding has decreased over last quarter: -8.11%
- −The company has delivered a poor sales growth of 0.59% over past five years.
- −Promoter holding is low: 22.5%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Newspaper Publication of financial results for the second quarter & half year ended September 30, 2026.
Reported nil re-lodgement transfer requests for physical shares in October 2026.
Board approved unaudited standalone and consolidated Q2 FY2026 results on November 11, 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 9 | 13 | 12 | 10 | 12 | 12 | 12 | 13 | 13 | 14 | 14 | 14 | 17 |
| Expenses + | 4 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 10 | 9 | 11 |
| Operating Profit | 5 | 6 | 5 | 4 | 6 | 6 | 5 | 5 | 5 | 5 | 4 | 5 | 6 |
| OPM % | 52.48% | 49.57% | 45.66% | 43.04% | 46.43% | 45.37% | 40.85% | 43.8% | 41.34% | 40.64% | 31.34% | 35.36% | 35.43% |
| Other Income + | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 0 | 2 | 1 | 0 | 6 | 1 | 1 | 1 | 2 | 2 | 0 | 0 | 2 |
| Tax % | 29.79% | 31.05% | 48.95% | 27.27% | 10.73% | 43.84% | 14.52% | 9.46% | 42.38% | 20.38% | 2,164.0% | 44.12% | 41.18% |
| Net Profit + | 0 | 1 | 1 | 0 | 5 | 1 | 1 | 1 | 1 | 1 | -5 | 0 | 1 |
| EPS in Rs | 0 | 1 | 1 | 0 | 4 | 1 | 1 | 1 | 0 | 1 | -2 | 0 | 1 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | -27 | -5 | -20 | -13 | 30 | -5 | 5 | 23 | 9 | 11 | 16 | 14 | 31 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 18 | 29 | 34 | 47 | 56 | 55 | 52 | 51 | 52 | 45 | 47 | 53 | 59 |
| Expenses + | 15 | 25 | 27 | 36 | 46 | 43 | 34 | 35 | 30 | 24 | 26 | 32 | 38 |
| Operating Profit | 3 | 4 | 8 | 11 | 10 | 12 | 18 | 16 | 22 | 21 | 21 | 22 | 21 |
| OPM % | 15.74% | 12.98% | 22.33% | 23.17% | 17.03% | 22.53% | 34.38% | 31.31% | 41.82% | 46.78% | 44.05% | 40.33% | 35.62% |
| Other Income + | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 2 |
| Interest | 1 | 0 | 1 | 2 | 3 | 3 | 4 | 4 | 8 | 8 | 8 | 6 | 6 |
| Depreciation | 3 | 3 | 4 | 5 | 5 | 5 | 6 | 7 | 9 | 9 | 9 | 11 | 13 |
| Profit before tax | 0 | 1 | 3 | 4 | 2 | 4 | 9 | 4 | 5 | 4 | 9 | 5 | 4 |
| Tax % | -142.11% | -16.67% | 11.66% | 21.95% | -23.08% | -4.47% | 34.11% | 50.78% | 42.64% | 37.93% | 17.18% | 135.55% | — |
| Net Profit + | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 3 | 3 | 7 | -2 | -3 |
| EPS in Rs | 0 | 1 | 3 | 3 | 2 | 3 | 4 | 2 | 2 | 2 | 4 | -1 | -1 |
| Dividend Payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | 10 | 61 | 19 | 38 | 19 | -1 | -6 | -1 | 2 | -13 | 3 | 14 | 18 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 0 | 1 | 3 | 9 | 15 | 20 | 29 | 33 | 37 | 40 | 61 | 71 | 72 |
| Borrowings + | 6 | 17 | 27 | 25 | 22 | 24 | 31 | 67 | 62 | 73 | 54 | 67 | 83 |
| Other Liabilities + | 27 | 19 | 11 | 15 | 6 | 6 | 6 | 8 | 9 | 10 | 11 | 18 | 20 |
| Total Liabilities | 41 | 46 | 51 | 60 | 55 | 64 | 80 | 122 | 123 | 137 | 143 | 178 | 197 |
| Fixed Assets + | 20 | 24 | 29 | 28 | 30 | 35 | 52 | 95 | 89 | 80 | 88 | 123 | 122 |
| CWIP | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 1 | 2 | 9 | 13 | 5 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22 | 24 |
| Other Assets + | 22 | 22 | 20 | 28 | 25 | 29 | 27 | 26 | 32 | 48 | 42 | 29 | 35 |
| Total Assets | 41 | 46 | 51 | 60 | 55 | 64 | 80 | 122 | 123 | 137 | 143 | 178 | 197 |
| Equity Capital | 9 | 9 | 9 | 10 | 12 | 13 | 13 | 14 | 15 | 15 | 17 | 22 | 22 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 2 | 9 | -6 | 11 | -1 | 9 | 14 | 17 | 15 | 16 | 12 | 35 |
| Cash from Investing Activity + | -2 | -7 | -12 | -5 | -4 | -10 | -23 | -51 | -4 | -8 | -16 | -59 |
| Cash from Financing Activity + | -1 | 0 | 7 | -3 | 1 | 2 | 9 | 35 | -11 | -8 | 4 | 25 |
| Net Cash Flow | -1 | 1 | -11 | 3 | -4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 2 | -18 | 6 | -4 | -2 | -9 | -34 | 11 | 8 | -4 | -3 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 81 | 234 | -70 | 110 | -13 | 68 | 96 | 118 | 77 | 80 | 65 | 166 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 57.92% | 57.92% | 57.92% | 57.91% | 61.12% | 59.16% | 60.94% | 64.84% | 64.84% | 64.58% | 69.39% | 77.5% |
| Promoters | 42.08% | 42.08% | 42.08% | 42.08% | 38.89% | 40.85% | 39.07% | 35.17% | 35.17% | 35.43% | 30.62% | 22.51% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Vivo Bio Tech Ltd. (this stock) | 35 | — | 0.37 | -2.24% |
| Medi Caps Ltd. | 33 | — | 0.27 | -9.21% |
| Gkb Ophthalmics Ltd. | 31 | 11.2 | 0.56 | 3.28% |
| Vivimed Labs Limited | 43 | — | -0.2 | — |
| Mangalam Drug & Chem Ltd | 45 | — | 0.51 | -35.3% |
| Ortin Global Limited | 11 | — | — | — |
| Sunil Healthcare Ltd. | 78 | 26.6 | 1.03 | 6.01% |
Which Mutual Funds Hold Vivo Bio Tech Ltd.?
Frequently Asked Questions about Vivo Bio Tech Ltd.
Vivo Bio Tech Ltd. (VIVOBIOT) closed at ₹14.32 on NSE on 19 November 2026, down 1.08 (7.01%) from the previous close.
Vivo Bio Tech Ltd. trades on the NSE (National Stock Exchange of India) under the symbol VIVOBIOT.
Vivo Bio Tech Ltd. has a dividend yield of 0.0%.
Vivo Bio Tech Ltd.'s 52-week high is ₹34.2 and its 52-week low is ₹12.0.
Vivo Bio Tech Ltd. has a market capitalisation of ₹35 crore.
Vivo Bio Tech Ltd. has a TopFund Quality Score of 31/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Vivo Bio Tech Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.